SMS Pharmaceuticals Reports 48% PAT Growth in FY26

Profit after tax grew 48% year-over-year to Rs 102 crore for SMS Pharmaceuticals Limited, driven by backward integration and product mix optimization. The company reported a 13% revenue increase to Rs 886.87 crore in FY26, reflecting strategic shifts toward high-margin APIs. Backward integration played a key role in expanding margins, with EBITDA rising 23% to Rs 171.28 crore. The board recommended a final dividend of Rs 0.40 per share, aligning with the company's profitability trajectory. This performance underscores the effectiveness of SMS Pharmaceuticals' focus on anti-inflammatory and ARV APIs, where scale advantages are becoming more pronounced.

Revenue from operations for FY26 expanded 13% to Rs 886.87 crore, supported by strong growth in key therapeutic segments. Anti-retroviral (ARV) APIs contributed Rs 251.80 crore, accounting for 28% of total revenue, while anti-inflammatory products added Rs 177.05 crore. The company optimized its portfolio by reducing investments in the anti-diabetic segment, which saw a 30% decline. Gross profit margins improved by 14 basis points to 34%, aided by cost efficiencies from backward integration. EBITDA margins also rose 155 basis points to 19%, highlighting the company's ability to convert revenue growth into profitability.

The Rs 280 crore capex program, aimed at completing by FY27, is progressing as planned. These investments will enhance manufacturing capacity for existing APIs, support new product pipelines, and bolster R&D capabilities. The company completed 12 drug master file (DMF) and current good manufacturing practice (CGMP) filings in FY26, with plans to submit 10 more in FY27. This capacity expansion and regulatory progress position SMS Pharmaceuticals to target over 15% revenue growth in FY27, supported by higher-margin APIs and structural cost advantages. The associate company VKT Pharma contributed Rs 14 crore to FY26 PAT, with expectations of sustained contributions in the future.

Looking ahead, SMS Pharmaceuticals aims to maintain its growth trajectory through product diversification and backward integration. The company's two manufacturing facilities in Hyderabad and Vizag, with combined capacities of 200 KL and 3,000 KL, provide a strong foundation for scaling operations. With a global customer base in over 70 countries, SMS Pharmaceuticals continues to strengthen its position in the API market. The board's focus on high-margin segments and capacity additions suggests a balanced approach to profitability and expansion. As the company navigates evolving market dynamics, its strategic emphasis on backward integration and R&D filings remains critical to sustaining long-term growth and shareholder value.

Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.